Abiopharma

🔍 Wafford Bill (Executive)

Company: QVC Group, Inc. (QVCGA)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 13,201 shares of Series A Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 13,305.00 | transaction_form_type: 4 | Footnotes: F1, F2, F1
• Sold 4,565 shares of Series A Common Stock at $2.86 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,740.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 13,201 shares of Restricted Stock Units - QVCGA (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F4, F4, F1

Footnotes:

• F1: On May 22, 2025, the issuer effected a 1-for-50 reverse stock split of all issued and outstanding shares of QVCGA common stock and QVCGB common stock. At the effective time of the reverse stock split, the number of shares subject to then-outstanding equity awards (including those held by the reporting person) were proportionately adjusted.
• F2: Reflects prior awards of restricted stock units previously reported in Table II of the reporting person's Form 3. Each restricted stock unit represented a contingent right to receive one share of QVCGA common stock. As of the date of this filing, the total reported in Column 5 includes 13,201 shares of QVCGA common stock underlying restricted stock units previously reported in Table II and 104 shares of QVCGA common stock, each as adjusted for the reverse stock split.
• F3: Represents shares withheld to satisfy the reporting person's tax liability in connection with the vesting of restricted stock units.
• F4: On May 23, 2023, the reporting person was granted 13,201 restricted stock units (as adjusted for the reverse stock split), vesting in full on March 20, 2026.